TICKERNERD
Menu
PALIPALIHealthcare · Biotechnology

PALI Stock Forecast: Palisade Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.06
+2.49% on the day

The 8 Wall Street analysts covering Palisade Bio, Inc. hold a median 12-month price target of $8 — +288.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$359.0M
Ticker Nerd rank
36 / 100
Median analyst target
$8.00
Analysts covering
8
Revenue$500K
Operating income−$11.7M
Net income−$10.6M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.5%
1M
−3.7%
YTD
−12.3%
1Y
+255.2%
From 52W high
−26.4%
From 52W low
+255.2%
$0.58
$2.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PALI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palisade Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
78
Size
58
Value
54
Volatility
51
Quality
50
Accruals
47
Revisions
32
Growth
30
Issuance
27

Momentum (78): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PALI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PALI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26PALIHigh $25.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $5.00Median $8.00High $25.00

The green dot is the last close — the median target sits +288.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 July 2026OppenheimerInitiatesOutperform$8.00
9 Apr 2026Wolfe ResearchInitiatesOutperform—
9 Apr 2026Wolfe ResearchInitiatesOutperform$7.00
26 Mar 2026HC Wainwright & Co.InitiatesBuy—
25 Feb 2026StifelInitiatesBuy—
9 Jan 2026B. Riley SecuritiesInitiatesBuy—
30 Dec 2025Clear StreetInitiatesBuy—
29 Dec 2025Piper SandlerInitiatesOverweight—
13 May 2025Brookline CapitalMaintainsBuy—
20 Nov 2024Brookline CapitalInitiatesBuy—
13 Nov 2024Maxim GroupMaintainsBuy—
1 May 2024Maxim GroupReiteratesBuy—
16 Apr 2024Maxim GroupMaintainsBuy—
17 Nov 2023Maxim GroupUpgradeBuy—
16 May 2023Ladenburg ThalmannMaintainsBuy—
30 Mar 2023Maxim GroupUpgradeBuy—
19 Aug 2022Maxim GroupDowngradeHold—
2 Feb 2022Ladenburg ThalmannInitiatesBuy—
31 Aug 2021Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PALI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PALI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Palisade Bio, Inc. returned +255.2% against +17.5% for the S&P 500, dividends included.

PALI vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26PALIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PALI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Palisade Bio, Inc. (PALI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.2×

Cheaper than 68% of US stocks

Price / sales
718.0×

Cheaper than 1% of US stocks

Price / book
2.9×

Cheaper than 34% of US stocks

EV / EBITDA
−6.6×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−2339.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−51.4%

Higher than 21% of US stocks

Return on assets
−33.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Palisade Bio, Inc. (PALI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Palisade Bio, Inc. has a market value of $359.0M and an enterprise value of $233.8M.

  • Revenue in the twelve months to 30 June 2026: $500K.

  • Net income over the same four quarters: −$31.9M, a −6388.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$18.2M.

  • Shares outstanding: 173.8M.

  • Trailing P/E: 3.2×; forward P/E: −7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Palisade Bio, Inc. employs 14 people — $36K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PALI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PALIPalisade Bio, Inc.$359.0M
36
OBIOOrchestra Biomed Holdings, Inc.$358.1M
38
CMPXCompass Therapeutics, Inc.$360.2M
32
RCKTRocket Pharmaceuticals, Inc.$362.5M
55
PRLDPrelude Therapeutics, Inc.$365.6M
95
SIONSionna Therapeutics, Inc.$350.3M
26
EYPTEyePoint, Inc.$350.2M
14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palisade Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PALI news & analysis

Palisade Bio to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Palisade Bio announced that members of its management will participate in three healthcare investor conferences in September 2026. The clinical-stage biopharmaceutical company develops next-generation prodrugs for patients with inflammatory and fibrotic diseases.

Why it matters — A Palisade Bio watcher would care because management's participation in investor conferences provides opportunities for the company to present its progress and engage with the investment community.

FAQ

Frequently asked questions about PALI stock

What is the PALI stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Palisade Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PALI stock a buy right now?

Of the 8 analysts covering Palisade Bio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palisade Bio, Inc. 36 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PALI?

As at 12 Sept 2026, Palisade Bio, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (78 of 100).

Will PALI stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +288.3% from the last close, and Ticker Nerd's factor model ranks Palisade Bio, Inc. 36 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PALI stock forecast for 2030?

No analyst covering Palisade Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PALI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $25 over the next 12 months.

How has PALI stock performed over the past year?

Palisade Bio, Inc. returned +255.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palisade Bio, Inc. do?

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases.

What is the latest news on PALI?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Palisade Bio to Participate in Upcoming Investor Conferences". Palisade Bio announced that members of its management will participate in three healthcare investor conferences in September 2026. The clinical-stage biopharmaceutical company develops next-generation prodrugs for patients with inflammatory and fibrotic diseases.

Company

About Palisade Bio, Inc.

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.

CEO Mr. J. D. Finley · 14 employees · United States · https://www.palisadebio.com